{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34710137",
  "DateCompleted": {
    "Year": "2021",
    "Month": "11",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "10",
        "Day": "28"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e0259061",
      "10.1371/journal.pone.0259061"
    ],
    "Journal": {
      "ISSN": "1932-6203",
      "JournalIssue": {
        "Volume": "16",
        "Issue": "10",
        "PubDate": {
          "Year": "2021"
        }
      },
      "Title": "PloS one",
      "ISOAbbreviation": "PLoS One"
    },
    "ArticleTitle": "Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.",
    "Pagination": {
      "StartPage": "e0259061",
      "MedlinePgn": "e0259061"
    },
    "Abstract": {
      "AbstractText": [
        "Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-8058-3423"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Boston VA Cooperative Studies Program (CSP) Center, VA Boston Healthcare System, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Fillmore",
        "ForeName": "Nathanael",
        "Initials": "N"
      },
      {
        "Identifier": [
          "0000-0001-6774-3149"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom."
          }
        ],
        "LastName": "Bell",
        "ForeName": "Steven",
        "Initials": "S"
      },
      {
        "Identifier": [
          "0000-0002-5416-2481"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Broad Institute of Harvard and MIT, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Shen",
        "ForeName": "Ciyue",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Boston VA Cooperative Studies Program (CSP) Center, VA Boston Healthcare System, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Nguyen",
        "ForeName": "Vinh",
        "Initials": "V"
      },
      {
        "Identifier": [
          "0000-0003-2266-0221"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Boston VA Cooperative Studies Program (CSP) Center, VA Boston Healthcare System, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "La",
        "ForeName": "Jennifer",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Rheumatology, VA Boston Healthcare System, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Dubreuil",
        "ForeName": "Maureen",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Infection Disease, VA Boston Healthcare System, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Strymish",
        "ForeName": "Judith",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Boston VA Cooperative Studies Program (CSP) Center, VA Boston Healthcare System, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Brophy",
        "ForeName": "Mary",
        "Initials": "M"
      },
      {
        "Identifier": [
          "0000-0002-5696-359X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute for Liver and Digestive Health, University College London, London, United Kingdom."
          },
          {
            "Identifier": [],
            "Affiliation": "Institute of Hepatology, Foundation for Liver Research, London, United Kingdom."
          }
        ],
        "LastName": "Mehta",
        "ForeName": "Gautam",
        "Initials": "G"
      },
      {
        "Identifier": [
          "0000-0002-7281-8579"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Wu",
        "ForeName": "Hao",
        "Initials": "H"
      },
      {
        "Identifier": [
          "0000-0002-6200-4715"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Lieberman",
        "ForeName": "Judy",
        "Initials": "J"
      },
      {
        "Identifier": [
          "0000-0001-6868-7011"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Boston VA Cooperative Studies Program (CSP) Center, VA Boston Healthcare System, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Section of General Internal Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Do",
        "ForeName": "Nhan",
        "Initials": "N"
      },
      {
        "Identifier": [
          "0000-0001-6059-6270"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America."
          },
          {
            "Identifier": [],
            "Affiliation": "Broad Institute of Harvard and MIT, Boston, Massachusetts, United States of America."
          }
        ],
        "LastName": "Sander",
        "ForeName": "Chris",
        "Initials": "C"
      }
    ],
    "GrantList": [
      {
        "GrantID": "DP1 HD087988",
        "Acronym": "HD",
        "Agency": "NICHD NIH HHS",
        "Country": "United States"
      },
      {
        "Acronym": "BHF_",
        "Agency": "British Heart Foundation",
        "Country": "United Kingdom"
      },
      {
        "GrantID": "K23 AR069127",
        "Acronym": "AR",
        "Agency": "NIAMS NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Observational Study",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, Non-P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "PLoS One",
    "NlmUniqueID": "101285081",
    "ISSNLinking": "1932-6203"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "TR3MLJ1UAI",
      "NameOfSubstance": "Disulfiram"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Alcoholism"
    },
    {
      "QualifierName": [
        "epidemiology",
        "metabolism"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cohort Studies"
    },
    {
      "QualifierName": [
        "metabolism",
        "therapeutic use"
      ],
      "DescriptorName": "Disulfiram"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Proportional Hazards Models"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Veterans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors have declared that no competing interests exist."
}